Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
出版年份 2019 全文链接
标题
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
作者
关键词
-
出版物
SCIENCE
Volume 366, Issue 6466, Pages 714-723
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2019-11-08
DOI
10.1126/science.aaw9032
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Cristina Saura et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
- (2018) Travis A. Clark et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Abstract 5371: The Metastatic Breast Cancer Project: Partnering with patients to accelerate progress in cancer research
- (2018) Nikhil Wagle et al. CANCER RESEARCH
- Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) inPIK3CA-mutated locally advanced or metastatic solid tumors
- (2018) Komal Jhaveri et al. CANCER RESEARCH
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition
- (2017) Sweta Maheshwari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
- (2017) Inma M. Berenjeno et al. Nature Communications
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
- (2016) Ronglai Shen et al. NUCLEIC ACIDS RESEARCH
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation
- (2015) Nuala A. O'Leary et al. NUCLEIC ACIDS RESEARCH
- Structural basis of nSH2 regulation and lipid binding in PI3Kα
- (2015) Michelle S. Miller et al. Oncotarget
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies
- (2013) Veena M. Singh et al. Annals of Diagnostic Pathology
- PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
- (2013) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Metrics other than potency reveal systematic variation in responses to cancer drugs
- (2013) Mohammad Fallahi-Sichani et al. Nature Chemical Biology
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
- (2012) Kathryn M. Kinross et al. JOURNAL OF CLINICAL INVESTIGATION
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Absolute quantification of somatic DNA alterations in human cancer
- (2012) Scott L Carter et al. NATURE BIOTECHNOLOGY
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 (PIK3CA)
- (2012) J. E. Burke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase
- (2011) Minghao Sun et al. CELL CYCLE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases
- (2011) W-C Hon et al. ONCOGENE
- The Sequence Alignment/Map format and SAMtools
- (2009) H. Li et al. BIOINFORMATICS
- A frequent kinase domain mutation that changes the interaction between PI3K and the membrane
- (2009) D. Mandelker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Real-Time DNA Sequencing from Single Polymerase Molecules
- (2008) J. Eid et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started